Dosing and administration

TYVERB is an oral medication, taken once per day, every day

Tyverb is an oral treatment that is presented as a 250 mg, yellow, oval tablet with the letters ‘GS XJG’ debossed on one side.

It is important that patients are given the correct pack for their indication, so that they take the correct dosage.

Tyverb in combination with trastuzumab

Learn more

Tyverb and trastuzumab are administered separately.

  • Tyverb is available in 84-tablet bottles, which covers a 3-week supply*
  • Intravenous trastuzumab is available as a 150 mg powder for concentrate for solution for infusion

In the treatment of HER2+ hormone receptor-negative (HR-) metastatic breast cancer, the recommended dosage of Tyverb is 1000 mg (four 250 mg tablets) taken orally once a day, continuously.1

When taken in combination with Tyverb, the dose of trastuzumab used in the pivotal study was 4 mg/kg administered as an intravenous (IV) loading dose, followed by 2 mg/kg IV weekly. Please refer to the full Summary of Product Characteristics for trastuzumab.2

A treatment cycle with Tyverb in combination with trastuzumab is 7 days. Tyverb plus trastuzumab 4 mg/kg is taken on Day 1. Tyverb alone is taken on Day 2 through to Day 7. At the end of the 7 days, the treatment cycle should be repeated with a trastuzumab dose of 2 mg/kg until disease progression or unacceptable toxicity.1

Further information on dosing and administration can be found in the Tyverb Summary of Product Characteristics.1

*Blister packs are available in some countries within Asia.

Tyverb in combination with trastuzumab: clinical evidence

References: 1. Tyverb® (lapatinib) Summary of Product Characteristics. Camberley, UK: Novartis Europharm Limited; 11 August 2015. 2. Herceptin (trastuzumab) Summary of Product Characteristics. Hertfordshire, UK: Roche Registration Limited; Last updated 12 October 2016.